Introduction: Polycystic ovary syndrome (PCOS) is, nowadays, considered the most common cause of infertility in women, a disabling syndrome not only due to its effects on fertility but also due to its manifestations on the physical appearance and general health.
Methods: We researched PubMed, Uptodate and Wiley databases analyzing relevant clinical trials and reviews on the subject of PCOS and myo-inositol (MI). Discussions: In our search of a treatment capable to address to the entire morpho-physiological panel of symptoms we encountered inositols.They since discovered that myo-inositol, as ovarian stimulator is associated with a pregnancy rate of 40%, it increases insulin sensitivity, lowers insulin and androgen levels having in the same time benefic effects on hirsutism. Our perspective. We intend to conduct a clinical trial enlisting at least 200 patients with PCOS who want to conceive, patients who will receive myo-inositol as primary treatment. When enlisting the patients we will form groups based on the PCOS phenotype with emphasis on anthropometric and morphologic characteristics,biochemical and ultrasonographic parameters, with follow-ups at 3 and 6 month of therapy.
Conclusions: Even though myo-inositol is not yet appraised as an effective treatment for PCOS in international guides we believe that overlooking its benefic effects is refusing a simple yet effective treatment. We believe that its relevance is being overlooked due to the small clinical trials, this being the main reason for our intent of conducting a larger study.Full text sources